Loading organizations...
Nuevocor develops genetic medicines designed to treat untreatable cardiomyopathies by targeting their underlying mechanical defects. The company’s lead program, NVC-001, is a novel therapy for LMNA-related dilated cardiomyopathy, an aggressive and rare heart condition. This approach centers on a mechanobiology-focused strategy to restore cardiac function, moving beyond symptomatic management.
Established in 2021, Nuevocor emerged from the critical need for effective treatments beyond cardiac transplants for patients suffering from devastating cardiomyopathies. The company's genesis was driven by the insight that addressing the aberrant mechanobiology of these diseases could offer viable alternatives where current therapeutic options are limited or non-existent.
Nuevocor’s therapies are intended for patients afflicted with life-threatening genetic cardiomyopathies, particularly those with conditions like LMNA-related dilated cardiomyopathy, who currently lack targeted treatments. The company's vision is to transform the treatment landscape for these conditions, aiming to provide innovative solutions for improved patient outcomes and quality of life.
Nuevocor has raised $80.6M across 3 funding rounds.
Nuevocor has raised $80.6M in total across 3 funding rounds.
Nuevocor has raised $80.6M across 3 funding rounds. Most recently, it raised $45.0M Series B in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $45M Series B | Elia Stupka, Amanda Gett Chaperot | First Star Ventures, Seventure Partners, Boehringer Ingelheim, Clavystbio, EDBI, Seeds Capital | Announced |
| Nov 3, 2022 | $11.6M Venture Round | — | — | Announced |
| Jun 18, 2021 | $24M Series A | Weiyi Zhang, Xiangqian (xq) LIN | EDBI, Seeds Capital, Xora Innovation | Announced |
Nuevocor has raised $80.6M in total across 3 funding rounds.
Nuevocor's investors include Elia Stupka, Amanda Gett-Chaperot, First Star Ventures, Seventure Partners, Boehringer Ingelheim, ClavystBio, EDBI, SEEDS Capital, Weiyi Zhang, XiangQian (XQ) Lin, Xora Innovation.
Nuevocor is a Singapore-headquartered IND-stage biotechnology company focused on developing novel genetic medicines to treat untreatable cardiomyopathies by addressing their underlying mechanical defects. Its lead product candidate, NVC-001, targets LMNA-related dilated cardiomyopathy (DCM), a rare and aggressive genetic heart disease with no current targeted therapies. Nuevocor’s approach leverages a proprietary mechanobiology platform called PrOSIA to identify shared disease pathways across multiple cardiomyopathies, aiming to provide one-time transformative therapies that improve patient outcomes and reduce reliance on cardiac transplants. The company serves patients with genetic cardiomyopathies and collaborates globally with leading experts to accelerate clinical development and innovation[1][2][3].
Founded in 2021 by Dr. Yann Chong Tan, an experienced biotech entrepreneur with multiple successful ventures, Nuevocor emerged from the recognition of a critical gap in cardiomyopathy treatment: despite over 30 known genetic mutations causing these diseases, only a handful were being actively researched due to limited understanding of their mechanistic causes. The idea was to develop a platform capable of mapping the mechanical defects underlying these conditions and rapidly translating insights into therapies. Early traction came from collaborations with Singapore’s A*STAR research institutes and securing significant funding rounds, including a $45 million Series B in 2025, enabling the company to advance its lead candidate into clinical trials[2][4][5].
Nuevocor is riding the wave of precision genetic medicine and mechanobiology, a cutting-edge trend that addresses diseases at their biomechanical root rather than solely at the genetic sequence level. The timing is critical as advances in gene therapy vectors, mechanobiology understanding, and regulatory acceptance converge to enable novel treatments for rare and previously untreatable cardiomyopathies. Market forces such as the growing burden of heart failure, unmet medical needs, and increasing investment in rare disease biotech favor Nuevocor’s innovative approach. By pioneering therapies that modulate disease pathways rather than replace genes, Nuevocor could reshape treatment paradigms and inspire further research into mechanobiology-driven diseases[1][2][3][4].
Nuevocor is poised to become a leader in mechanobiology-based genetic therapies with its upcoming clinical trials for NVC-001 marking a significant milestone. Future trends shaping its journey include advances in gene delivery technologies, deeper mechanistic insights into cardiomyopathies, and expanding global collaborations. As the company progresses, it may broaden its pipeline to address other genetic cardiomyopathies and potentially other mechanobiology-related diseases. Its influence is likely to grow as a model for integrating mechanobiology with gene therapy, potentially transforming treatment options for patients with rare and complex heart conditions[1][2][3][4].
